What is HC Wainwright’s Estimate for HURA Q2 Earnings?

TuHURA Biosciences (NASDAQ:HURA) – Stock analysts at HC Wainwright issued their Q2 2025 EPS estimates for shares of TuHURA Biosciences in a report issued on Monday, March 3rd. HC Wainwright analyst R. Burns forecasts that the company will earn ($0.20) per share for the quarter. HC Wainwright currently has a “Buy” rating and a $13.00 price target on the stock. HC Wainwright also issued estimates for TuHURA Biosciences’ Q3 2025 earnings at ($0.12) EPS, Q4 2025 earnings at ($0.11) EPS, Q1 2026 earnings at ($0.10) EPS and Q2 2026 earnings at ($0.11) EPS.

Several other research analysts have also weighed in on HURA. Rodman & Renshaw initiated coverage on shares of TuHURA Biosciences in a research note on Thursday, December 19th. They issued a “buy” rating and a $11.00 price objective on the stock. RODMAN&RENSHAW raised shares of TuHURA Biosciences to a “strong-buy” rating in a research note on Thursday, December 19th.

TuHURA Biosciences Stock Performance

Shares of HURA opened at $2.04 on Thursday. The firm has a 50-day simple moving average of $4.08. TuHURA Biosciences has a fifty-two week low of $1.89 and a fifty-two week high of $14.60.

Hedge Funds Weigh In On TuHURA Biosciences

Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Accent Capital Management LLC acquired a new position in shares of TuHURA Biosciences during the 4th quarter worth $29,000. TT Capital Management LLC acquired a new position in TuHURA Biosciences during the fourth quarter worth $41,000. Jefferies Financial Group Inc. acquired a new position in TuHURA Biosciences during the fourth quarter worth $54,000. Bank of America Corp DE bought a new position in TuHURA Biosciences during the fourth quarter valued at about $59,000. Finally, Charles Schwab Investment Management Inc. acquired a new stake in shares of TuHURA Biosciences in the fourth quarter worth about $61,000. Institutional investors own 0.62% of the company’s stock.

About TuHURA Biosciences

TuHURA Biosciences, Inc (NASDAQ: HURA) is a Phase 3 registration-stage immuno-oncology company developing novel technologies to overcome resistance to cancer immunotherapy. TuHURA’s lead innate immune response agonist candidate, IFx-2.0, is designed to overcome primary resistance to checkpoint inhibitors.